

## **Karolinska Development's portfolio company OssDsign raises SEK 93 million (EUR 9.6 million)**

**STOCKHOLM - November 4, 2015. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign AB has successfully raised SEK 93 million (EUR 9.6 million) in a new equity financing. The financing is led by the new investors SEB Venture Capital and Fouriertransform with continued investment from Karolinska Development. The proceeds will be used for the market expansion of OssDsign's product line of unique craniofacial implants based on an innovative material technology with excellent biological and biomechanical properties.**

OssDsign's first products – Craniomosaic and Sculpter for cranioplasty and facial reconstruction, respectively – have been successfully launched in Germany, United Kingdom and the Nordic countries, and further expansion in Europe is scheduled for 2016. The company is working with regulatory authorities to expand access for its products in new key markets, with clearance expected in the US in 2016.

Karolinska Development was the lead investor when OssDsign was founded in 2011 and today's follow-on investment confirms its strong belief in the further growth of the company and its ability to generate value for its shareholders.

“This financing of OssDsign is an important example of our core strategy to pro-actively syndicate our investments with recognized specialist investors such as SEB Venture Capital and Fouriertransform. Both of our new co-investors in OssDsign have an excellent track record of making successful investments within this sector and we are very pleased to have them on board. With these new funds, OssDsign will be able to deliver a number of key commercial and developmental value inflection milestones with their innovative implant product line,” comments Jim Van heusden, CEO of Karolinska Development.

OssDsign, based in Uppsala (Sweden), is a medtech company dedicated to creating regenerative implants for improved healing of bone defects and deficits in skull, facial and other types of surgery. For more information, go to [www.ossdsign.com](http://www.ossdsign.com)

**For further information, please contact:**

Jim Van heusden, CEO, Karolinska Development AB

Phone: +46 72 858 32 09, e-mail: [jim.van.heusden@karolinskadevelopment.com](mailto:jim.van.heusden@karolinskadevelopment.com)

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson

Phone: +44 20 7638 9571; e-mail: [KDev@citigatedr.co.uk](mailto:KDev@citigatedr.co.uk)

## TO THE EDITORS

### **About Karolinska Development AB**

Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of 12 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.

For more information, please visit [www.karolinskadevelopment.com](http://www.karolinskadevelopment.com)

*This constitutes information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is legally obliged to publish under the Securities Market Act and/or the Financial Instruments Trading Act.*